BAJAJ BROKING
The Indian government has invited bids from merchant bankers to manage stake sales in PSU banks and listed financial institutions. The process aims to meet SEBI's 25% public shareholding rule. Read more..Potential candidates include IOB, Central Bank of India, Punjab & Sind Bank, UCO Bank, and LIC. Bank of Maharashtra share price movement may reflect market sentiment. Read less
The Department of Investment and Public Asset Management (DIPAM) has issued a request for proposal (RFP) inviting merchant bankers to manage the stake sale in select public sector banks (PSBs) and listed public financial institutions (PFIs). The selected bankers will advise the government on the equity dilution process and will be empanelled for three years, extendable by one year. This move aligns with the government’s disinvestment strategy to enhance liquidity and public participation in state-owned financial entities.
Also read: NTPC & NTPC Green Energy to Invest ₹2 Lakh Crore in Madhya Pradesh
Biocon Biologics introduces YESINTEK in the US, a biosimilar alternative to Stelara.
It is approved for Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis.
Available in multiple formulations, including 45 mg/0.5 mL PFS and 130 mg/26 mL vial.
FDA approved YESINTEK in December 2024, confirming its similarity to Stelara.
Biocon share price closed at ₹321.30 on BSE, down 0.23%.
Also read: Biocon Biologics Launches YESINTEK Biosimilar in US for Autoimmune Diseases
YESINTEK’s launch in the US expands treatment accessibility for patients suffering from autoimmune diseases. The biosimilar, a monoclonal antibody, disrupts IL-12 and IL-23 mediated signaling, essential in immune-mediated conditions. Clinical trials demonstrated comparable efficacy, safety, and immunogenicity profiles to Stelara, supporting its FDA approval.
YESINTEK will be available in the same formulations as Stelara, ensuring seamless transition for healthcare providers and patients. Additionally, a patient assistance programme has been introduced, offering benefits verification, copay support, and financial assistance, with eligible patients paying as little as $0 under the scheme.
Formulation | Dosage |
Pre-Filled Syringe (PFS) | 45 mg/0.5 mL |
Pre-Filled Syringe (PFS) | 90 mg/mL |
Vial | 45 mg/0.5 mL |
Vial | 130 mg/26 mL |
Following the announcement, Biocon share price declined slightly, closing at ₹321.30 on BSE, reflecting a 0.23% dip. Investors are closely monitoring the biosimilar’s market reception, as its successful uptake could impact Biocon’s revenue and market positioning in the biologics segment.
Biocon Biologics’ launch of YESINTEK strengthens its biosimilar portfolio and reinforces its commitment to expanding affordable treatment options in the US. As one of the first Stelara biosimilars in the market, YESINTEK could drive competition, benefiting patients and healthcare providers alike. The industry will be watching closely for market adoption trends and future biosimilar launches from Biocon.
Also read: ONGC Approves ₹1,200 Crore Investment in ONGC Green for PTC Energy Buy
Do you have a trading account app or demat account app?
You can open an account with Bajaj Broking in minutes.
Download the Bajaj Broking app now from Play Store or App Store.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://www.bajajbroking.in/disclaimer
Share this article:
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading